Qiagen shareholder says Thermo Fisher offer ‘inadequate’

Add to My Stories Print page Add to Favourites

Davidson Kempner Capital Management says that it considers Thermo Fisher Scientific’s current offer to acquire German genetic test maker Qiagen to be “inadequate” and would not tender its shares into…